| scholarly article | Q13442814 |
| P356 | DOI | 10.1111/NYAS.12809 |
| P698 | PubMed publication ID | 26099690 |
| P2093 | author name string | Tariq Sethi | |
| Claire Rooney | |||
| P2860 | cites work | Genome-wide association study identifies five loci associated with lung function | Q24629653 |
| Meta-analyses of genome-wide association studies identify multiple loci associated with pulmonary function | Q24633262 | ||
| The natural history of chronic airflow obstruction | Q24674578 | ||
| A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema | Q28205534 | ||
| Genetics of sputum gene expression in chronic obstructive pulmonary disease | Q28740314 | ||
| Genome-wide association analysis of blood biomarkers in chronic obstructive pulmonary disease | Q29416995 | ||
| A variant associated with nicotine dependence, lung cancer and peripheral arterial disease | Q29614871 | ||
| Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper | Q29614960 | ||
| Design of the Subpopulations and Intermediate Outcomes in COPD Study (SPIROMICS). | Q30405591 | ||
| A genome-wide association study in chronic obstructive pulmonary disease (COPD): identification of two major susceptibility loci. | Q33419815 | ||
| Candidate genes for COPD in two large data sets | Q33609447 | ||
| Variants in FAM13A are associated with chronic obstructive pulmonary disease | Q33687879 | ||
| Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial | Q33711672 | ||
| Mathematical modeling of GATA-switching for regulating the differentiation of hematopoietic stem cell. | Q33840296 | ||
| Genetic epidemiology of COPD (COPDGene) study design | Q34074731 | ||
| Airway count and emphysema assessed by chest CT imaging predicts clinical outcome in smokers | Q34184260 | ||
| Identification of a chronic obstructive pulmonary disease genetic determinant that regulates HHIP. | Q34238083 | ||
| Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype | Q34280020 | ||
| Genome-wide study identifies two loci associated with lung function decline in mild to moderate COPD. | Q34300307 | ||
| Loci identified by genome-wide association studies influence different disease-related phenotypes in chronic obstructive pulmonary disease | Q34535065 | ||
| THE SLOW SPACE IN CHRONIC OBSTRUCTIVE PULMONARY DISEASES | Q34541416 | ||
| The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease | Q34546085 | ||
| Refining susceptibility loci of chronic obstructive pulmonary disease with lung eqtls | Q34922245 | ||
| Serum PARC/CCL-18 concentrations and health outcomes in chronic obstructive pulmonary disease | Q35042489 | ||
| The chronic bronchitic phenotype of COPD: an analysis of the COPDGene Study | Q35201858 | ||
| Physiological and radiological characterisation of patients diagnosed with chronic obstructive pulmonary disease in primary care | Q35533974 | ||
| Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. | Q35537270 | ||
| COPD association and repeatability of blood biomarkers in the ECLIPSE cohort | Q35637295 | ||
| Multi-dimensional phenotyping: towards a new taxonomy for airway disease. | Q36292293 | ||
| Computed tomography-based biomarker provides unique signature for diagnosis of COPD phenotypes and disease progression | Q36385615 | ||
| Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality | Q36421917 | ||
| Dissecting direct and indirect genetic effects on chronic obstructive pulmonary disease (COPD) susceptibility. | Q36691602 | ||
| The clinical importance of dynamic lung hyperinflation in COPD. | Q36760103 | ||
| Gene expression analysis uncovers novel hedgehog interacting protein (HHIP) effects in human bronchial epithelial cells | Q36862051 | ||
| Blood fibrinogen as a biomarker of chronic obstructive pulmonary disease | Q37012728 | ||
| COPD phenotype description using principal components analysis | Q37233745 | ||
| Club cell protein 16 and disease progression in chronic obstructive pulmonary disease | Q37566520 | ||
| The COPD Biomarker Qualification Consortium (CBQC). | Q38109909 | ||
| A meta-analysis on the prophylactic use of macrolide antibiotics for the prevention of disease exacerbations in patients with Chronic Obstructive Pulmonary Disease | Q38114571 | ||
| Rehospitalizations among patients in the Medicare fee-for-service program | Q39513280 | ||
| Chronic obstructive pulmonary disease phenotypes: the future of COPD. | Q39867138 | ||
| Derivation and validation of a composite index of severity in chronic obstructive pulmonary disease: the DOSE Index. | Q39942398 | ||
| Circulating fibronectin to C-reactive protein ratio and mortality: a biomarker in COPD? | Q40045917 | ||
| Inflammatory biomarkers and exacerbations in chronic obstructive pulmonary disease | Q44077968 | ||
| Health status and the spiral of decline | Q44368782 | ||
| Identification and prospective validation of clinically relevant chronic obstructive pulmonary disease (COPD) subtypes | Q44406271 | ||
| Quantitative analysis of lungs and airways with CT in subjects with the chronic obstructive pulmonary disease (COPD) candidate FAM13A gene: case control study for CT quantification in COPD risk gene | Q44535407 | ||
| Dissociation of lung function and airway inflammation in chronic obstructive pulmonary disease. | Q44917822 | ||
| Use of factor analysis to consolidate multiple outcome measures in chronic obstructive pulmonary disease | Q45713366 | ||
| Biopsy neutrophilia, neutrophil chemokine and receptor gene expression in severe exacerbations of chronic obstructive pulmonary disease | Q45863625 | ||
| Serum surfactant protein D is steroid sensitive and associated with exacerbations of COPD. | Q46150950 | ||
| Lung function in type 2 diabetes: the Normative Aging Study. | Q46807123 | ||
| A multidimensional grading system (BODE index) as predictor of hospitalization for COPD. | Q47674749 | ||
| Pulmonary rehabilitation and the BODE index in COPD. | Q47716426 | ||
| Bronchiectasis, exacerbation indices, and inflammation in chronic obstructive pulmonary disease. | Q47984688 | ||
| Two-year improvement in multidimensional body mass index, airflow obstruction, dyspnea, and exercise capacity index after nonresectional lung volume reduction surgery in awake patients. | Q48544349 | ||
| Development and first validation of the COPD Assessment Test. | Q49053189 | ||
| Expansion of the prognostic assessment of patients with chronic obstructive pulmonary disease: the updated BODE index and the ADO index. | Q50598579 | ||
| Clusters of comorbidities based on validated objective measurements and systemic inflammation in patients with chronic obstructive pulmonary disease. | Q50724186 | ||
| Changes in forced expiratory volume in 1 second over time in COPD. | Q51521679 | ||
| Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double-blind, placebo-controlled trial. | Q51729130 | ||
| Genetic epidemiology of severe, early-onset chronic obstructive pulmonary disease. Risk to relatives for airflow obstruction and chronic bronchitis. | Q52241091 | ||
| Factor analysis of quality of life, dyspnea, and physiologic variables in patients with chronic obstructive pulmonary disease before and after rehabilitation. | Q53496286 | ||
| Factor analysis of exercise capacity, dyspnoea ratings and lung function in patients with severe COPD. | Q54210698 | ||
| Inflammatory Biomarkers Improve Clinical Prediction of Mortality in Chronic Obstructive Pulmonary Disease | Q57955696 | ||
| Susceptibility to Exacerbation in Chronic Obstructive Pulmonary Disease | Q57955820 | ||
| Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE) | Q57955885 | ||
| Evaluation of serum CC-16 as a biomarker for COPD in the ECLIPSE cohort | Q58316998 | ||
| Infections and Airway Inflammation in Chronic Obstructive Pulmonary Disease Severe Exacerbations | Q58877199 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | biomarker | Q864574 |
| P304 | page(s) | 18-32 | |
| P577 | publication date | 2015-06-01 | |
| P1433 | published in | Annals of the New York Academy of Sciences | Q2431664 |
| P1476 | title | Biomarkers for precision medicine in airways disease. | |
| P478 | volume | 1346 |
| Q38821380 | Machine learning approaches to personalize early prediction of asthma exacerbations |
| Q55256527 | Physiological and biological characterization of smokers with and without COPD. |
| Q38690517 | Plasma Fibrinogen Qualification as a Drug Development Tool in Chronic Obstructive Pulmonary Disease. Perspective of the Chronic Obstructive Pulmonary Disease Biomarker Qualification Consortium |
| Q38678093 | Precision respiratory medicine and the microbiome |
Search more.